11Apr 2023
Stopping COVID-19 Complications Before They Start: The CARE Study on Rivaroxaban

Stopping COVID-19 Complications Before They Start: The CARE Study on Rivaroxaban

A clinical trial called the COVID Antithrombotic Rivaroxaban Evaluation (CARE) study aimed to evaluate the effectiveness of antithrombotic prophylaxis with rivaroxaban in reducing the risk of venous or arterial thrombotic events, invasive ventilatory support, and death in COVID-19 outpatients. The study is a multicenter, randomized, open-label, controlled trial with a primary composite endpoint of venous thromboembolism, invasive mechanical ventilation, major acute cardiovascular events, and mortality within 30 days of randomization. The trial will provide important information about the potential role of thromboprophylaxis in outpatients with COVID-19.

  • #family health

Like

Save

Share